Teva Interim Chief Legal Officer Dov Bergwerk Files Initial Form 3 Holdings Report

Executive Summary

On October 8, 2026, Dov Bergwerk, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd ($TEVA), filed an initial Form 3 statement of beneficial ownership with the SEC. The report establishes ownership as of September 29, 2026, disclosing direct ownership of 11,943 ordinary shares alongside multiple tranches of stock options and restricted share units.

Holdings Breakdown

• Ordinary Shares: 11,943 shares held directly.
• Stock Options:
  • 17,505 options with an exercise price of $34.70, expiring March 3, 2027 (fully vested).
  • 8,755 options with an exercise price of $28.98, expiring May 24, 2027 (fully vested).
• Restricted Share Units (RSUs):
  • 16,742 RSUs (granted Nov 15, 2023, vesting through Nov 2027).
  • 16,742 RSUs (granted Mar 4, 2024, vesting through Mar 2028).
  • 10,719 RSUs (granted Mar 5, 2025, vesting through Mar 2029).
  • 13,673 RSUs (granted Mar 4, 2026, vesting through Mar 2030).
  • 7,771 RSUs (granted Mar 3, 2023, vesting through Mar 2027).

Market Significance

This is a standard administrative filing following the insider becoming subject to Section 16 reporting requirements as Interim Chief Legal Officer. As there are no market purchases or sales involved, this filing carries low immediate trading significance for Teva investors.